The Drug Enforcement Administration is asking farmers and growers to grow 4,000 pounds of cannabis and 1,500 pounds of mushrooms in 2022 for research. The agency hopes the access will allow them to better understand how drugs interact with each other through plant models.
The “dea psychedelics” is a new research project that will see the US government grow way more cannabis and mushrooms in 2022. The DEA has asked for people to help with this project.
In order to conduct research, the DEA will need much more marijuana and mushrooms in 2022.
Marijuana’s worldwide popularity isn’t going away anytime soon. This has instilled hope among marijuana supporters that additional study and, potentially, federal legalization will follow. Such aspirations for legalization are fueled by news such as the DEA’s request for additional cannabis and psychedelics for study in the year 2022.
The DEA is urging a large-scale increase in production.
The DEA has issued a formal request for a significant increase in research-based psychedelics and cannabis production by 2022. According to Marijuana Moment, the Federal government will announce its interest in a notice set to be published on Monday that has piqued the cannabis industry’s curiosity.
The DEA previously boosted its psilocybin and cannabis quotas for 2021 in September 2021, but is now seeking for even more research-grade cannabis with a wider range of psychedelics to be produced in 2022.
The most notable is MDMA, which has a strategy to double the amount of cannabis extracts, psilocin and psilocybin, quadruple mescaline, and quintuple DMT. The DEA wants to boost drug manufacturing by 6,300 percent, from 50 grams in 2021 to 3,200 grams in 2022. More investigation into the drug’s medicinal potential will be conducted.
While LSD will see a 1.150 percent rise, up to 500 grams of the potent psychedelic, cannabis would see a 60 percent increase, from 2 million grams in 2020 to 3.2 million grams in 2022 under the new DEA plan.
The reason behind the rise in cannabis and psychedelics research
The DEA said in its Register Notice that it has been receiving and approving new applications from groups that want to “grow, synthesize, extract, and produce dosage forms containing schedule 1 hallucinogenic drugs for clinical study reasons.”
The DEA also claims to encourage “Regulated” research using schedule 1 controlled drugs, as seen by their anticipated increase in output in 2022 above what was available in 2021.
Because there is presently just one farm at the University of Mississippi that permits for cannabis production for research reasons, the agency said it was working aggressively to evaluate and approve cannabis producers’ applications.
The following is a breakdown of the DEA’s rise in clinical trial applications:
-
Methylendioxymethamphetamine levels have risen by 3.4 percent (MDMA)
-
5-Methoxy-N-N-Dimethyltryptamine
-
Dimethyltryptamine
-
Diethylamide of lysergic acid (LSD)
-
Marihuana
-
Extract of Marijuana is a kind of marijuana that is used to treat a variety
-
Mescaline
-
Psilocybin
-
Psilocyn
-
Tetrahydrocannabinols (THC)
These increases will help fund manufacturing operations connected to the increased research and clinical trials with schedule 1 restricted drugs.
The following is a breakdown of the actual figures for the quotas in 2021 and 2022:
|
Substance |
Figures for 2021 |
Figures proposed for 2022 |
|
MDA |
55 |
200 |
|
5-MeO-DMT |
35 |
550 |
|
DMT |
50 |
250 |
|
Mescaline |
25 |
100 |
|
LSD |
40 |
500 |
|
MDMA |
50 |
3,200 |
|
Psilocyn |
1.000 |
2.000 |
|
Psilocybin |
1,500 |
3,000 |
|
Tetrahydrocannabinol (THC) |
1,000 |
2,000 |
|
Marijuana Extract |
500,000 |
1,000,000 |
|
Marijuana |
2,000,000 |
3.,200,000 |
The public’s, researchers’, and experts’ roles
Following the publication of the notice on Monday, the agency will have a 30-day feedback period during which individuals may voice their opinions on the new quotas. It’s also worth noting that these developments are occurring as a result of public interest in marijuana.
There will be no need to expand the quotas established in 2021 if individuals do not want to investigate cannabis. The DEA acknowledges that it can no longer ignore the growing “scientific and public” interest in cannabis and psychedelics, which will lead to further clinical studies. All of these clinical studies demonstrate that cannabis has medicinal potential and might be used in medicine.
Nora Volkov, the Director of the National Institute on Drug Abuse, claims that the agency’s planned increase in the production limit has encouraged her. She also said that studies have consistently shown that the benefits of psychedelics may encourage more individuals to try psilocybin.
The tight laws that classify these natural gifts as a schedule 1 substance irritate experts, researchers, and advocates for these fungus. They claim that certain chemicals should not be classified as “dangerous” since they have medicinal usefulness for certain illnesses.
A petition to have the DEA reassess cannabis scheduling under the Controlled Substances Act was denied by a federal appeal court in August. However, following the judgment, a judge issued a concurring opinion, stating that the agency may be forced to review a policy change. Because the medicinal benefit of marijuana has been misunderstood, these adjustments may be essential.
In a second petition, the Washington State attorney general’s office and attorneys representing cancer patients requested a federal appeals court to allow the DEA to amend its policy. The policy change is intended to enable persons receiving end-of-life medical treatment to use psilocybin under federal and state “Right to Try” regulations. Researchers and professionals are taking these steps to demonstrate to the DEA that it has been waging a losing war against cannabis for a long time. It is now time to let nature’s gift to us to have a good influence on the lives of Americans.
Although there is a lot of anticipation for what will happen in 2022, one can only wonder how far we would have come if we had begun much sooner. Hopefully, this step will persuade other states that haven’t legalized marijuana to reevaluate their positions and adopt a more proactive approach.
Conclusion
When a government agency, like as the DEA, increases its quota on a material or expresses such strong interest in it, it says a lot about it. Yes, marijuana remains primarily illegal at the federal level, which should be a solid reason for the DEA to avoid any marijuana-related discussions.
Nonetheless, here we are, reading great news about the possibilities of growing cannabis production for research reasons. This demonstrates that so much more will happen in the cannabis sector in 2022, and the DEA is already preparing for it. The more marijuana research done, the more likely it is that additional marijuana-based products will be created for commercial usage. What an exciting moment to be a cannabis aficionado, as the business continues to grow in 2022!!
Watch This Video-
The “spravato” is a device that can be used to grow cannabis and mushrooms. The DEA wants you to grow way more of these plants in 2022 for research purposes.
Related Tags
- dea rescheduling 2021
- psychedelic news 2021
- sisley v dea
- esketamine
